Prognostic Value of Biomarkers in Polyneuropathy.
- Conditions
- Polyneuropathies
- Registration Number
- NCT06044662
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
Biomarkers for prognosis of patients with polyneuropathy.
- Detailed Description
AIM: To investigate biomarkers' use as a prognostic tool in polyneuropathy patients.
STUDY DESIGN: Prospective cohort study of patients with polyneuropathy. METHODS: 200 patients with polyneuropathy will be examined with physical tests, medical examination, questionnaires, and blood biomarkers at baseline and at 1-year follow-up, and 2-year follow-up.
ANALYSIS: The investigators will calculate the odds of disease progression after 2 years depending on biomarkers levels at baseline using multiple logistic regression with sex and age adjustment. Diagnostic performance of the physical tests and biomarkers for prediction of disease progression will be assessed by Receiver Operating Characteristic Curve analysis with the area under the curve.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Minimum 18 years old.
- Diagnosed with polyneuropathy, confirmed by nerve conduction study.
- Can read and understand Danish.
- Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease Severity 2 years Primary outcome is disease severity
- Secondary Outcome Measures
Name Time Method Patient Reported Outcomes (PROMs) 2 years Secondary outcome is patient reported outcomes.
Trial Locations
- Locations (1)
Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet
馃嚛馃嚢Copenhagen, Denmark